Estonia - Esti - Ravimiamet

bausch health ireland limited - asatiopriin - õhukese polümeerikattega tablett - 25mg 90tk; 25mg 28tk; 25mg 100tk; 25mg 50tk; 25mg 56tk

Estonia - Esti - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 500mg 1tk

Estonia - Esti - Ravimiamet

sandoz pharmaceuticals d.d. - asatiopriin - õhukese polümeerikattega tablett - 75mg 50tk

Estonia - Esti - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 40mg 1tk

Estonia - Esti - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 250mg 1tk

Estonia - Esti - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 125mg 1tk

Estonia - Esti - Ravimiamet

sandoz pharmaceuticals d.d. - asatiopriin - õhukese polümeerikattega tablett - 100mg 100tk; 100mg 50tk

Estonia - Esti - Ravimiamet

aspen pharma trading limited - asatiopriin - õhukese polümeerikattega tablett - 50mg 100tk

Estonia - Esti - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 1000mg 1tk

Uni Eropa - Esti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.